Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03948035
Title Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Wuerzburg University Hospital
Indications

multiple myeloma

Therapies

Carfilzomib + Dexamethasone + Lenalidomide

Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide

Age Groups: senior | adult
Covered Countries


No variant requirements are available.